Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00458079 | Prostate | BPH | positive regulation of endocytosis | 32/3107 | 100/18723 | 1.09e-04 | 9.95e-04 | 32 |
GO:00320929 | Prostate | BPH | positive regulation of protein binding | 28/3107 | 85/18723 | 1.65e-04 | 1.43e-03 | 28 |
GO:00074099 | Prostate | BPH | axonogenesis | 98/3107 | 418/18723 | 1.68e-04 | 1.45e-03 | 98 |
GO:00147066 | Prostate | BPH | striated muscle tissue development | 91/3107 | 384/18723 | 1.90e-04 | 1.57e-03 | 91 |
GO:00315796 | Prostate | BPH | membrane raft organization | 12/3107 | 25/18723 | 2.63e-04 | 2.06e-03 | 12 |
GO:00072668 | Prostate | BPH | Rho protein signal transduction | 39/3107 | 137/18723 | 3.37e-04 | 2.53e-03 | 39 |
GO:00510906 | Prostate | BPH | regulation of DNA-binding transcription factor activity | 100/3107 | 440/18723 | 4.71e-04 | 3.37e-03 | 100 |
GO:00018199 | Prostate | BPH | positive regulation of cytokine production | 105/3107 | 467/18723 | 5.18e-04 | 3.66e-03 | 105 |
GO:00017653 | Prostate | BPH | membrane raft assembly | 7/3107 | 11/18723 | 6.10e-04 | 4.16e-03 | 7 |
GO:00426926 | Prostate | BPH | muscle cell differentiation | 88/3107 | 384/18723 | 7.59e-04 | 5.01e-03 | 88 |
GO:001593110 | Prostate | BPH | nucleobase-containing compound transport | 55/3107 | 222/18723 | 1.12e-03 | 6.97e-03 | 55 |
GO:00316238 | Prostate | BPH | receptor internalization | 32/3107 | 113/18723 | 1.21e-03 | 7.41e-03 | 32 |
GO:002240915 | Prostate | BPH | positive regulation of cell-cell adhesion | 67/3107 | 284/18723 | 1.41e-03 | 8.40e-03 | 67 |
GO:00510924 | Prostate | BPH | positive regulation of NF-kappaB transcription factor activity | 40/3107 | 152/18723 | 1.54e-03 | 9.08e-03 | 40 |
GO:00482599 | Prostate | BPH | regulation of receptor-mediated endocytosis | 31/3107 | 110/18723 | 1.56e-03 | 9.16e-03 | 31 |
GO:00510916 | Prostate | BPH | positive regulation of DNA-binding transcription factor activity | 62/3107 | 260/18723 | 1.58e-03 | 9.23e-03 | 62 |
GO:00622086 | Prostate | BPH | positive regulation of pattern recognition receptor signaling pathway | 15/3107 | 44/18723 | 3.59e-03 | 1.83e-02 | 15 |
GO:1901890 | Prostate | BPH | positive regulation of cell junction assembly | 28/3107 | 104/18723 | 5.18e-03 | 2.43e-02 | 28 |
GO:00350237 | Prostate | BPH | regulation of Rho protein signal transduction | 24/3107 | 86/18723 | 5.71e-03 | 2.65e-02 | 24 |
GO:00430621 | Prostate | BPH | extracellular structure organization | 67/3107 | 302/18723 | 6.67e-03 | 3.00e-02 | 67 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04910 | Colorectum | MSS | Insulin signaling pathway | 43/1875 | 137/8465 | 7.37e-03 | 2.84e-02 | 1.74e-02 | 43 |
hsa049101 | Colorectum | MSS | Insulin signaling pathway | 43/1875 | 137/8465 | 7.37e-03 | 2.84e-02 | 1.74e-02 | 43 |
hsa049102 | Colorectum | FAP | Insulin signaling pathway | 36/1404 | 137/8465 | 2.51e-03 | 1.18e-02 | 7.18e-03 | 36 |
hsa049103 | Colorectum | FAP | Insulin signaling pathway | 36/1404 | 137/8465 | 2.51e-03 | 1.18e-02 | 7.18e-03 | 36 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491021 | Liver | Cirrhotic | Insulin signaling pathway | 56/2530 | 137/8465 | 3.74e-03 | 1.50e-02 | 9.26e-03 | 56 |
hsa0491031 | Liver | Cirrhotic | Insulin signaling pathway | 56/2530 | 137/8465 | 3.74e-03 | 1.50e-02 | 9.26e-03 | 56 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa049108 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491023 | Oral cavity | EOLP | Insulin signaling pathway | 33/1218 | 137/8465 | 1.61e-03 | 5.60e-03 | 3.30e-03 | 33 |
hsa0491033 | Oral cavity | EOLP | Insulin signaling pathway | 33/1218 | 137/8465 | 1.61e-03 | 5.60e-03 | 3.30e-03 | 33 |
hsa049107 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
hsa0491012 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
hsa0491022 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
hsa0491032 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FLOT1 | SNV | Missense_Mutation | | c.782N>A | p.Arg261Gln | p.R261Q | O75955 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
FLOT1 | insertion | Frame_Shift_Ins | novel | c.476_477insGTCAAGCACATGCAAATGTGGCATGACTTATTGGGAGCAGAAAC | p.Asp159GlufsTer61 | p.D159Efs*61 | O75955 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
FLOT1 | insertion | Nonsense_Mutation | novel | c.381_382insAATATATTTTACATAAGGTGTCTTTAAACAGAAACA | p.Phe127_Ser128insAsnIlePheTyrIleArgCysLeuTerThrGluThr | p.F127_S128insNIFYIRCL*TET | O75955 | protein_coding | | | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
FLOT1 | insertion | Frame_Shift_Ins | novel | c.508_509insGCTGTGCCCGTGCAAAGGAG | p.Ala170GlyfsTer42 | p.A170Gfs*42 | O75955 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
FLOT1 | SNV | Missense_Mutation | rs568759969 | c.692G>A | p.Arg231Gln | p.R231Q | O75955 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FLOT1 | SNV | Missense_Mutation | novel | c.1138C>A | p.Leu380Met | p.L380M | O75955 | protein_coding | tolerated(1) | benign(0.007) | TCGA-VS-A9V0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
FLOT1 | SNV | Missense_Mutation | | c.11N>T | p.Thr4Ile | p.T4I | O75955 | protein_coding | tolerated(0.06) | benign(0.257) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FLOT1 | SNV | Missense_Mutation | | c.83N>T | p.Arg28Leu | p.R28L | O75955 | protein_coding | tolerated(0.16) | probably_damaging(0.964) | TCGA-AA-3989-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
FLOT1 | SNV | Missense_Mutation | | c.245N>A | p.Ala82Glu | p.A82E | O75955 | protein_coding | tolerated(0.27) | possibly_damaging(0.544) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
FLOT1 | SNV | Missense_Mutation | rs201200201 | c.1240N>A | p.Val414Met | p.V414M | O75955 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |